Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmasoft
Hypothesis: Mexidol® allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function
Age
50–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
An advanced stage of POAG in one or two eyes
Hypotonic-compensated intraocular pressure (IOP)
You may not be if
Degenerative diseases of the central nervous system, diabetes mellitus
Primary mitochondrial dysfunction
A history of surgical interventions and damage to the organ of vision
Acute or chronic inflammatory or hereditary degenerative eye diseases (anterior and posterior sections)
Decompensation of concomitant somatic diseases
Taking antioxidants/nootropic drugs 6 months before inclusion in the study
Hypersensitivity to ethylmethylhydroxypyridine succinate or to any of the excipients
Clareo Health | MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
